Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

NDAQ:SLS - Post by User

Sellas Life Sciences Group Inc

Bullboard Posts

Post by BerkshireCapGrpon Jun 19, 2019 12:27am

171 Views

Post# 29838626

SLS .17 NASDAQ BIOTECH .50++ CENTS PT

SLS IS A STEAL DOWN HERE ON NASDAQ. WAY DOWN FROM $1++ THE OFFERING COMPLETED YESTERDAY FOR $15 MILLION. PHASE III TRIALS ARE NEXT. THIS HAS HUGE POTENTIAL BUT FOR SHORT TERM WE ARE LOOKING FOR .50++ CENTS THEN POSSIBLE. 70++ CENTS TO $1++

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute